1 / 54

CARBOHYDRATE S METABOLISM DISORDERS

CARBOHYDRATE S METABOLISM DISORDERS. GLUCOSE METABOLISM. the cornerstone of life neurons are especially dependent on glucose regulatory mechanisms: hyperglycemic hormones = glycogenolysis, gluconeogenesis hypoglycemic hormone = insulin. HYPERGLICEMIA (diabetes mellitus).

haile
Download Presentation

CARBOHYDRATE S METABOLISM DISORDERS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. CARBOHYDRATES METABOLISM DISORDERS

  2. GLUCOSE METABOLISM • the cornerstone of life • neurons are especially dependent on glucose • regulatory mechanisms: • hyperglycemic hormones = glycogenolysis, gluconeogenesis • hypoglycemic hormone = insulin

  3. HYPERGLICEMIA(diabetes mellitus) • Diabetes - Greek word = to siphon or to pass thru. • Mellitus - Latin word = sweet or honey. • group of chronic disorders • insulin deficiencyABSOLUTE/RELATIVE !!! also affects protein and fat metabolism

  4. CLASSIFICATION • type 1 DM - autoimmune pancreatic β-cell destruction = absolute insulin deficiency; • type 2 DM - insulin resistance = relative insulin deficiency; • “other” specific types of DM (associated with identifiable clinical conditions or syndromes); • gestational DM - appears or is first detected during pregnancy.

  5. !!! pre-diabetes • impaired glucose tolerance (IGT) • impaired fasting glucose (IFG)

  6. ADA diagnosis of DM 1.classic symptoms of diabetes (polyuria, polydipsia, and unexplained weight loss) plus random plasma glucose concentration ≥ 200 mg/dL (≥11.1 mmol/L);or 2.fasting (≥8-hour) plasma glucose concentration ≥ 126 mg/dL (≥7.0 mmol/L);or 3.   a 2-hour postload plasma glucose concentration ≥ 200 mg/dL (≥11.1 mmol/L) during a 75-g oral glucose tolerance test.

  7. ETIOLOGY Type 1 diabetes • Genetic • Environmental • Autoimmune

  8. Type 2 diabetes = relative insulin deficiency – insulin resistance / inadequate secretory response • complex genetic interactions unrelated to HLA genes • environmental factors such as body weight (obesity) and exercise (lack of physical activity).

  9. MODY • autosomal dominant inheritance • onset in at least 1 family member younger than 25 years • absence of autoantibodies • correction of fasting hyperglycemia without insulin for at least 2 years • absence of ketosis.

  10. Type 2 DM pathogenic mechanisms: • progressive loss of insulin secretory capacity. • impaired insulin action : • impaired mitochondrial function and the resulting accumulation of free fatty acids in insulin-responsive tissues. • defects of the insulin receptor. • defects in “postreceptor” pathways • Adipocyte-Derived Hormones and Cytokines • Leptin • Adiponectin • other adipocyte-derived factors (resistin, angiotensinogen, interleukin-6, transforming growth factor-β, plasminogen activator inhibitor 1) • TNF-α.

  11. Glucotoxicity. • Lipotoxicity. • accelerate hepatic gluconeogenesis • inhibit muscle glucose metabolism • impair pancreatic β-cell function.

  12. Type 1 DM produces profound β-cell failure and insulin deficiency with secondary insulin resistance, • Type 2 DM is associated with less severe insulin deficiency but greater insulin resistance.

  13. diabetes mellitus pathogenesis

  14. fasting hyperglycemia • mobilization of substrates from muscle and adipose tissue • accelerated hepatic gluconeogenesis, glycogenolysis, ketogenesis • impaired removal of endogenous and exogenous fuels by insulin-responsive tissues.

  15. fasting free fatty acids • Insuline deficiency - increase lipolysis • Glucagon - accelerating hepatic ketogenesis • Catecholamines growth hormone, and cortisol - increase lipolysis. • type 1 diabetes- converted to ketone bodies • type 2 diabetes– insulin suppress the conversion of free fatty acids to ketones !!! The increase in substrate delivery - hepatic steatosis and severe hypertriglyceridemia (endogenous).

  16. Postprandial Hyperglycemia • type 1 diabetes – insulin deficiency • type 2 diabetes - delayed insulin secretion + hepatic insulin resistance • the liver fails to arrest glucose production • fails to appropriately take up glucose for storage as glycogen • glucose uptake by peripheral tissues is impaired

  17. Hyperglycaemia  renal threshold for glucose surpassed (>170mg/dl)  GLUCOSURIA  osmotic diuresis  POLYURIA  dehydration  thirst  POLYDIPSIA

  18. Type 1 diabetic- defects in the disposal of ingested proteins and fats as well. • Hyperaminoacidemia • Hypertriglyceridemia (exogenous)

  19. ACUTE METABOLIC COMPLICATIONS • diabetic ketoacidosis (DKA) • hyperosmolar hyperglycemic syndrome (HHS) • hypoglycemia

  20. DKA • deficient circulating insulin activity • excessive secretion of counter-regulatory hormones. • hyperglycemia, ketosis, acidosis !!! osmotic diuresis - dehydration and electrolyte loss.

  21. Hyperosmolar Hyperglycemic Syndrome (HHS) • patients cannot drink enough liquid to keep pace with a vigorous osmotic diuresis. • Severe hyperosmolarity (>320 mOsm/L) • Severe hyperglycemia (>600 mg/dL). • severe acidosis and ketosis are generally absent in the HHS!!!

  22. Hypoglycemia • the earliest subjective warning signs = autonomic symptoms (sweating, tremor, palpitations) • Central nervous system symptoms and signs = neuroglycopenia: • nonspecific (e.g., fatigue or weakness) • more clearly neurologic (e.g., double vision, oral paresthesias, slurring of speech, apraxia, personality change, or behavioral disturbances). • irreversible brain damage. • Hypoglycemic unawareness syndrome • duration of diabetes • autonomic neuropathy • switched to intensive insulin regimens.

  23. Somogyi phenomenon – • normal or increased blood glucose levels at bedtime • blood glucose drops in early morning hours (2 to 3 A.M.) usually because nighttime insulin dose is too high. • compensate by producing counterregulatory hormones resulting in hyperglycemia on awakening. • Dawn phenomenon=Decrease in the tissue sensitivity to insulin between 5 and 8 A.M. - prebreakfast hyperglycemia ??? release of nocturnal growth hormone

  24. CHRONIC DIABETIC COMPLICATIONSMICROVASCULAR AND NEUROPATHIC COMPLICATIONS • Intracellular glucose • advanced glycationend products (AGEs) • accelerated polyol pathway • reactive oxygen species • Others: cytokines, angiotensin II, endothelin, growth factor stimulation, depletion of basement membrane glycosaminoglycans • Hemodynamic changes in the microcirculation

  25. Diabetic retinopathy • vascular-neuroinflammatory disease. • breakdown of the blood-retinal barrier (BRB) function and loss of retinal neurons. • activated macroglia and neuronal death. • activated microglia exacerbate the damage.

  26. Diabetic Nephropathy • rise in glomerular filtration rate. • glomerular lesions • increased glomerular permeability. • microalbuminuria (30 to 300 mg/day) • diffuse glomerulosclerosis • massive proteinuria - nephrotic syndrome • Systemic hypertension • progression to ESRD.

  27. Diabetic Neuropathy • metabolic factors • vascular • Nerve growth factor diminished • Autoimmune mechanisms.

  28. Distal symmetrical (sensorimotor) polyneuropathy • Acute sensory neuropathy • Focal diabetic neuropathies (mononeuropathies) – pain • Entrapment syndromes • Proximal motor neuropathy (diabetic amyotrophy)

  29. Autonomic neuropathy • Cardiovascular abnormalities • preferential dysfunction of parasympathetic fibers • impaired sympathetic vasoconstrictor response and impaired cardiac reflexes. • Altered gastrointestinal function • hypermotility / hypomotility • Gastroparesis

  30. Genitourinary alterations • bladder hypotonia • Erectile dysfunction • Abnormal sweat production • Xerosis. • Distal anhidrosis - truncal-facial sweating • Generalized anhidrosis

  31. atherosclerosis • lipid abnormalities • procoagulant state = accentuated platelet aggregation and adhesion, endothelial cell dysfunction. • hyperinsulinemia

  32. The diabetic foot • chronic sensorimotor neuropathy • vascular disease • abnormal immune function

  33. HYPOGLICEMIA • Physiological hypoglycaemia • 3-5 hours after ingestion of glucose or during prolonged fast • Pathological HYPOGLICEMIA Whipple’s triad: • LOW BLOOD GLUCOSE below 50 mg/dl • symptoms of hypoglycaemia • symptoms relieved by glucose

  34. Classification: • Fasting hypoglycaemia • With hyperinsulinemia • Without hyperinsulinemia • Non-fasting, postprandial or reactive hypoglycaemia

  35. Fasting hypoglycemia with hyperinsulinemia • diabetes • islet cell tumours • factitious hypoglycemia • autoimmune hypoglycaemia • drugs

  36. Fasting hypoglycemia without hyperinsulinemia • Chronic renal impairment • Decreased renal gluconeogenesis • impaired hepatic glycogenolysis and gluconeogenesis !!! • increased insulin half-life due to decreased renal degradation • exaggerated glucose-induces insulin secretion

  37. severe liver disease = hepatogenous hypoglycaemia • deficient caloric intake and exercise-induced hypoglycaemia

  38. septicaemia early phase - hyperglycemia • decrease in insulin-stimulated phosphorylation of insulin receptor • increased clearance of insulin • increased production of corticosteroids. late phase – hypoglycemia • cytokines from macrophages stimulates insulin secretion • direct hypoglycemic effect of endotoxins (inhibit gluconeogenesis) • association of renal failure.

More Related